Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Up 304.7% in July

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 34,800 shares, agrowthof304.7% from the July 15th total of 8,600 shares. Based on an average daily volume of 44,600 shares, the short-interest ratio is currently 0.8 days. Approximately3.7% of the shares of the stock are short sold. Approximately3.7% of the shares of the stock are short sold. Based on an average daily volume of 44,600 shares, the short-interest ratio is currently 0.8 days.

Titan Pharmaceuticals Price Performance

TTNP stock opened at $4.99 on Friday. The business has a fifty day moving average price of $4.40 and a 200 day moving average price of $4.10. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80. The stock has a market capitalization of $4.54 million, a price-to-earnings ratio of -1.69 and a beta of 1.29.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings data on Thursday, August 14th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen started coverage on Titan Pharmaceuticals in a report on Tuesday, May 20th. They set a “sell” rating for the company.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.